| The domesticity maven has maintained her innocence, saying she had an agreement with her broker to sell the stock if it dropped below $60 "
She added, "It's sort of the American way to go up and down the ladder, maybe several times in a lifetime
It was her first lengthy media interview on the subject since news broke last June that federal prosecutors were investigating Stewart's sale of ImClone System Inc "I can be concerned on one hand, and be productive on the other hand The stock subsequently plummeted 19 interview took place at Stewart's Westport, Conn
Stewart told New Yorker writer Jeffrey Toobin that the losses have been mostly in the decline of her more than 30 million shares in her multimedia company, but also in legal fees and lost business opportunities "
, home for several hours with several of her advisers, the magazine said
"I'm real lucky, because I am able to sort of compartmentalize," she said
Stewart, chairman and chief executive of Martha Stewart Living Omnimedia, discussed her sentiments about the probe and the public reaction "And that I have been turned into or vilified openly as something other than what I really am has been really confusing And I've had a real long up
Stewart is a friend of Sam Waksal, a co-founder of ImClone
Federal prosecutors are increasing pressure on Stewart concerning her sale of 3,928 ImClone shares on Dec Stewart Says Probe Cost Her About $400M
Jan 26, 5:35 PM EST
Martha Stewart estimates the federal investigation into her ImClone stock trade has cost her about $400 million, according to an interview with The New Yorker magazine, which reaches newsstands Monday "
The Jan
In coming weeks, officials in the Justice Department and the Securities and Exchange Commission will decide whether to charge Stewart with securities law violations And now I've had a long way down
Stewart noted that her image has suffered and said she's "puzzled by the public's delight" in her troubles She would not speak on the record about the facts of the case and a magazine spokeswoman declined to say whether Stewart's lawyer was present
shares
Stewart said she'd never leave her company, and has been able to stay focused on her business 27, the day before the Food and Drug Administration announced it would not review the biotech company's application for a promising cancer drug called Erbitux I can still sleep
"My business is about homemaking," she said |